CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, is drawing attention as it develops novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses.
Shares closed Thursday at $3.16, up 0.13 percent, within a day's range of $3.16 to $3.28. The company's 52-week range spans $1.42 to $4.26, with an intraday market capitalization of $45.5 million. Trading volume of 14,098 shares was below the average of 50,179, reflecting a relatively quiet session despite the company's active clinical and corporate updates.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.